CYNDI MITCHELL: Open Payments
NPI 1861104861 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$585 in 25 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $897 · 2025 $585
Food & beverage: $585
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $271 |
| Novo Nordisk Inc | 4 | $73 |
| GlaxoSmithKline, LLC. | 2 | $55 |
| Lilly USA, LLC | 2 | $37 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| ABBVIE INC. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
Products named: AIRSUPRA, FARXIGA, TRELEGY ELLIPTA, BREZTRI, Wegovy, MOUNJARO, Ozempic, Kerendia.
Industry payments across KS — which companies pay providers there.
